ArticleGut microbes2026
Assessing the proinflammatory potential of sterile fecal microbiome filtrate from ulcerative colitis patients using an intestine-on-chip platform and automated image analysis.
Article in Gut microbes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsUlcerative colitis (UC) is characterized by disruptions of the gut microbiome and an exaggerated mucosal immune response in genetically susceptible individuals. Alterations in the composition of the intestinal metabolome associated with dysbiosis can trigger chronic inflammation. However, it remains unclear whether microbial dysbiosis is the cause or consequence of chronic mucosal inflammation. To address this gap, we aimed to investigate the potential pro-inflammatory effects of sterile fecal microbiome filtrate (FMF) using a microphysiological, immunocompetent intestine-on-chip (IoC) model.
methodsSterile FMF from UC patients with active disease (
resultsFMF from active UC patients significantly increased proinflammatory cytokines (IL-1β, IL-6, IL-8, IL-23, and MCP-1) in the vascular IoC compartment in a time-dependent manner. In contrast, FMF from non-UC or UC patients in remission had no significant impact on the proinflammatory cytokine response compared to untreated media control. Luminal-vascular permeability was increased following the FMF treatment regardless of its origin. Image-based analysis revealed increased epithelial tissue damage and reduced tissue thickness following FMF exposure, alongside decreased endothelial cell density and altered macrophage morphology, independent of UC disease activity.
conclusionsFMF from UC patients with active disease induces a robust proinflammatory cytokine response in the IoC model, suggesting that UC-associated FMF-derived factors may contribute to the initiation of inflammatory processes relevant to UC pathogenesis. These findings are derived from a simplified intestinal barrier model and require further mechanistic and physiological validation. While image analysis revealed no significant microarchitectural differences among the three FMF groups, the pipelines established standardized metrics to evaluate the impact of FMF-derived factors on intestinal tissue integrity and immune responses, providing a framework for future IoC-based research in UC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.